Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 2021 March;63(1) > Panminerva Medica 2021 March;63(1):21-7

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

SPECIAL ARTICLE  MULTIPLE MYELOMA IN 2020: STATE OF THE ART (PART II) Freefree

Panminerva Medica 2021 March;63(1):21-7

DOI: 10.23736/S0031-0808.20.04149-X

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Monoclonal antibodies in multiple myeloma

Federico VOZELLA 1 , Francesca FAZIO 2, Gianfranco LAPIETRA 2, Maria T. PETRUCCI 2, Giovanni MARTINELLI 3, Claudio CERCHIONE 3

1 Division of Hematology, San Giovanni di Dio Hospital, Florence, Italy; 2 Unit of Hematology, Department of Translational and Precision Medicine, Umberto I Polyclinic Hospital, Sapienza University, Rome, Italy; 3 Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Forlì-Cesena, Italy



Treatment of multiple myeloma (MM) patients has radically changed over the last years following the introduction of next generation proteasome inhibitors (PI) and immunomodulatory derivative (IMiDs). In the last years, one further therapeutic option for MM patients is represented by monoclonal antibodies (MoAbs), that seem to change the paradigm of MM treatment, particularly for heavily pretreated or double refractory to a PI and IMiDs patients. Antibodies have an immune-based mechanism, induce durable responses with limited toxicity and combine well with existing therapies. The therapeutic effects are prevalently obtained by means of antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell-mediated phagocytosis (ADCP), complement-dependent cytotoxicity (CDC) and concurrently by the induction of signals on cell effectors. Immunotherapeutic strategies offer a new and exciting approach to target key molecular pathways that continue to be implicated in the survival of malignant plasma cells. These targets include cell surface proteins (CD38, CD138 [SDC1], B cell maturation antigen [BCMA, TNFRSF17]), cytokines that play a role in plasma cell survival and proliferation (interleukin 6 [IL6] and B cell activating factor), signal regulators of bone metabolism (RANKL [TNFSF11], DKK1) and regulators of the immune system (PD-1[PDCD1], PD-L1[CD274]). This article focuses on new MoAbs and related innovative immunotherapeutic modalities currently under investigation in the treatment landscape of MM.


KEY WORDS: Multiple myeloma; Immunotherapy; Antibodies, monoclonal

top of page